Atossa Genetics Inc (ATOS)
2.54
-0.07 -2.68%
NASDAQ
May 24, 11:45
Delayed 2m
USD
View All Key Stats
ATOS Key Stats
| Income Statement | |
| Revenue (TTM) | -- |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -6.13 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -13.60M |
| Profitability | |
| Gross Profit Margin (Quarterly) | -- |
| Profit Margin (Quarterly) | -- |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | Upgrade |
| Price and Valuation | |
| Market Cap | 23.18M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | -- |
| PE Ratio (TTM) | -- |
| Price to Book Value | 1.189 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | Upgrade |
| Free Cash Flow (Quarterly) | -2.149M |
| Return on Equity (TTM) | Upgrade |
View All ATOS News
ATOS News
-
WireHeadlineTime (ET)
-
MT Newswires05/14 15:50
-
MT Newswires05/13 17:44
-
MT Newswires05/13 17:39
-
SA Breaking News05/13 17:28
-
Globe Newswire05/13 17:21
-
Yahoo04/30 06:10
-
SA Breaking News04/26 09:11
-
SA Breaking News04/25 12:52
-
Globe Newswire04/25 12:00
-
PR Newswire04/24 09:31
View All Events
ATOS Events
| Date | Type | Description |
|---|---|---|
| 05/16/2019 16:30 EDT | Misc | Atossa Genetics Inc First Quarter Earnings Conference Call in 2019 |
| 11/14/2018 | Earnings | Atossa Genetics Inc Third Quarter Earnings Results in 2018 |
ATOS Fundamentals
Income Statement View Statement
ATOS Ratings
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
Advertisement
ATOS One Page Reports
- One Page Report Download
Edit
Profile
- URL: https://www.atossagenetics.com
- Investor Relations URL: http://ir.atossagenetics.com/
- HQ State/Province: Washington
- Sector: Healthcare
- Industry: Diagnostics & Research
- Equity Style: Small Cap/Value
- Next Earnings Release: N/A
- Last Earnings Release: Nov. 14, 2018
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Atossa Genetics Inc is a clinical-stage pharmaceutical company operating in the US. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The clinical-Stage Programs of the company includes delivery of therapeutics through microcatheters which delivers a number of therapeutics to the ducts in the breast, the site of the majority of early breast cancers and fulvestrant Delivered through microcatheters which delivers fulvestrant as a potential treatment of ductal carcinoma in-situ (DCIS) and breast cancer. In addition, the company involves in the process of evaluating additional potential indications of endoxifen and other therapeutic candidates to treat breast conditions, including breast cancer.
ATOS Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 2.54 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Excel Add-In Codes
- Name: =YCI("ATOS","name")
- Description: =YCI("ATOS","description")
- Sector: =YCI("ATOS","sector")
- Industry: =YCI("ATOS","industry")
- Est. Current Fiscal Year End: =YCI("ATOS","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Other ATOS Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- ATOS Tweets Stocktwits
Advertisement
